Suppliers and packagers for kalydeco

kalydeco

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-300-01	56 GRANULE in 1 CARTON (51167-300-01)	2015-03-23
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-400-01	56 GRANULE in 1 CARTON (51167-400-01)	2015-03-23
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-600-01	56 GRANULE in 1 CARTON (51167-600-01)	2019-04-29

Kalydeco (Ivacaftor) Supply Chain Landscape

Last updated: February 19, 2026

This report details the key suppliers and manufacturing partners involved in the production of Kalydeco (ivacaftor), a drug used to treat specific mutations of cystic fibrosis. Analysis focuses on Vertex Pharmaceuticals' reliance on contract manufacturing organizations (CMOs) and specialized chemical suppliers for Active Pharmaceutical Ingredient (API) synthesis and drug product formulation. Understanding these supply chain dependencies is critical for assessing manufacturing capacity, potential risks, and competitive positioning.

Who are the Primary Suppliers for Kalydeco's Active Pharmaceutical Ingredient (API)?

The synthesis of ivacaftor, the API in Kalydeco, involves complex multi-step chemical processes. Vertex Pharmaceuticals, the innovator of Kalydeco, relies on a combination of internal manufacturing capabilities and outsourced partners to secure its API supply. While specific supplier contracts are proprietary, industry analysis and patent filings indicate the involvement of specialized chemical manufacturers. These entities possess the expertise and infrastructure for chiral synthesis and the handling of complex organic molecules.

• Specialized Chemical Manufacturers: Companies with a proven track record in producing advanced intermediates and APIs for the pharmaceutical sector are typically engaged. These suppliers must adhere to stringent Good Manufacturing Practices (GMP) and demonstrate robust quality control systems.
• Internal Vertex Manufacturing: Vertex Pharmaceuticals maintains its own manufacturing facilities, which likely contribute to a portion of the ivacaftor API production. This dual-sourcing strategy mitigates risks associated with sole-reliance on external partners.

What are the Key Stages in Kalydeco's API Synthesis?

The chemical synthesis of ivacaftor is a multi-step process. While a detailed step-by-step breakdown is proprietary, general stages involve the coupling of key chemical fragments. The process demands precise control over reaction conditions, including temperature, pressure, and reagent stoichiometry, to ensure high purity and yield.

1. Intermediate Synthesis: Precursor molecules are synthesized through a series of chemical reactions. This stage often involves multiple reaction vessels and purification steps.
2. Fragment Coupling: The synthesized intermediate fragments are brought together in specific chemical reactions to form the ivacaftor molecule. This is a critical step requiring careful optimization.
3. Purification: Crude ivacaftor is subjected to rigorous purification techniques, such as chromatography and recrystallization, to remove impurities and meet pharmaceutical standards.
4. Drying and Milling: The purified API is dried to a specified moisture content and milled to achieve the desired particle size distribution, essential for downstream drug product formulation.

Which Contract Manufacturing Organizations (CMOs) are involved in Kalydeco's Drug Product Formulation?

Beyond API synthesis, the formulation of ivacaftor into its final dosage form (tablets) is typically handled by specialized CMOs. These facilities are equipped for large-scale tablet manufacturing, coating, and packaging, operating under strict regulatory oversight. Vertex likely partners with multiple CMOs to ensure sufficient global supply and to diversify its manufacturing base.

• Key CMO Capabilities:
  • Tablet Compression: High-speed tablet presses capable of producing millions of tablets daily.
  • Film Coating: Application of specialized coatings for stability, taste masking, and controlled release.
  • Packaging and Labeling: Automated packaging lines for blister packs, bottles, and cartons, including serialization and track-and-trace capabilities.
  • Quality Assurance and Control: Comprehensive testing of raw materials, in-process samples, and finished products.

Based on typical industry practices and publicly available information regarding Vertex's manufacturing network, potential CMO partners include large, global pharmaceutical contract manufacturers known for their expertise in solid oral dosage forms. Specific names are generally not disclosed by pharmaceutical companies due to confidentiality agreements.

What is the Role of Excipient Suppliers in Kalydeco Manufacturing?

Excipients are inactive ingredients that play a crucial role in the formulation of Kalydeco tablets. They facilitate the manufacturing process, ensure drug stability, and affect drug release profiles. The quality and consistency of these excipients are paramount.

• Common Excipients in Oral Solid Dosage Forms:
  • Diluents (Fillers): Add bulk to the tablet. Examples include microcrystalline cellulose, lactose, and dicalcium phosphate.
  • Binders: Hold the tablet ingredients together. Examples include povidone, hydroxypropyl cellulose.
  • Disintegrants: Help the tablet break apart in the gastrointestinal tract. Examples include croscarmellose sodium, sodium starch glycolate.
  • Lubricants: Prevent sticking to manufacturing equipment. Examples include magnesium stearate, stearic acid.
  • Glidants: Improve powder flow. Examples include colloidal silicon dioxide.
  • Coating Agents: Provide a protective layer. Examples include hypromellose, titanium dioxide, polyethylene glycol.

Suppliers of these excipients are typically large, global chemical and pharmaceutical ingredient manufacturers that meet rigorous quality standards, including GMP certification.

How Does Vertex Pharmaceuticals Manage its Kalydeco Supply Chain?

Vertex Pharmaceuticals employs a multi-faceted approach to manage its Kalydeco supply chain, prioritizing quality, reliability, and compliance.

• Supplier Qualification and Auditing: Rigorous processes are in place to vet and continuously audit all critical suppliers, ensuring they meet Vertex's standards for quality, safety, and ethical conduct.
• Dual and Multi-Sourcing Strategies: For critical raw materials and manufacturing steps, Vertex likely utilizes dual or multi-sourcing to reduce reliance on a single supplier and mitigate supply chain disruptions.
• Quality Agreements: Detailed quality agreements are established with each supplier, outlining specific quality control measures, testing requirements, and change control procedures.
• Inventory Management: Robust inventory management systems are employed to ensure adequate stock levels of raw materials, intermediates, and finished products, balancing supply assurance with inventory costs.
• Regulatory Compliance: All aspects of the supply chain must adhere to global pharmaceutical regulations, including FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other national health authorities.

What are the Key Regulatory Considerations for Kalydeco's Suppliers?

Suppliers involved in the Kalydeco supply chain are subject to extensive regulatory oversight. Compliance with pharmaceutical manufacturing standards is non-negotiable.

• Good Manufacturing Practices (GMP): All API manufacturers and CMOs must operate under current GMP guidelines. This includes strict protocols for:
  • Facility design and maintenance.
  • Equipment qualification and calibration.
  • Personnel training and hygiene.
  • Process validation.
  • Quality control testing.
  • Record-keeping and documentation.
• Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory agencies (e.g., FDA). These confidential documents provide detailed information about the manufacturing process, facilities, and controls for the API. Pharmaceutical companies reference these DMFs in their drug applications.
• Change Control: Any changes to manufacturing processes, materials, or facilities by a supplier must undergo a formal change control process, requiring Vertex's review and approval to ensure no adverse impact on drug quality or regulatory status.
• Site Inspections: Regulatory agencies and Vertex conduct regular site inspections of supplier facilities to verify ongoing compliance with GMP and quality agreements.

What are the Potential Risks and Mitigation Strategies in the Kalydeco Supply Chain?

The complex nature of pharmaceutical supply chains presents inherent risks that Vertex must actively manage.

• Supply Disruption:
  • Risk: Natural disasters, geopolitical instability, supplier financial distress, or unexpected manufacturing issues can halt production.
  • Mitigation: Dual/multi-sourcing, maintaining safety stock of critical materials, strong supplier relationships with transparent communication, and robust business continuity plans.
• Quality Failures:
  • Risk: Contamination, out-of-specification materials, or process deviations can lead to batch rejection and product recalls.
  • Mitigation: Stringent supplier qualification, detailed quality agreements, comprehensive testing regimes, regular audits, and robust change control management.
• Regulatory Non-Compliance:
  • Risk: A supplier's failure to meet GMP or other regulatory requirements can lead to production stoppages and regulatory action.
  • Mitigation: Ongoing monitoring of supplier compliance, regular audits, clear communication of regulatory expectations, and prompt remediation of any identified issues.
• Intellectual Property (IP) Infringement:
  • Risk: Unauthorized use or disclosure of proprietary manufacturing processes.
  • Mitigation: Strong contractual protections, confidentiality agreements, and thorough due diligence on supplier IP practices.

How are Raw Material Prices and Availability Influenced?

The cost and availability of raw materials for Kalydeco API synthesis are subject to global market dynamics.

• Market Volatility: Prices for precursor chemicals and specialty reagents can fluctuate based on global demand, production capacity, energy costs, and geopolitical factors.
• Supplier Capacity: Limited specialized manufacturing capacity for complex intermediates can constrain availability and drive up prices.
• Regulatory Burden: The high cost of compliance with stringent pharmaceutical manufacturing regulations can influence the pricing of APIs and intermediates.
• Geographic Concentration: If key raw material suppliers are geographically concentrated, regional events can have a disproportionate impact on availability.

Vertex likely mitigates price and availability risks through long-term supply agreements, strategic inventory management, and by actively monitoring global commodity markets and supplier capacities.

Key Takeaways

• Vertex Pharmaceuticals employs a hybrid manufacturing strategy for Kalydeco, utilizing both internal facilities and contract manufacturing organizations (CMOs) for API synthesis and drug product formulation.
• The company relies on specialized chemical manufacturers for the complex multi-step synthesis of ivacaftor API.
• Excipient suppliers play a critical role, providing inactive ingredients essential for tablet formulation, stability, and drug delivery.
• Robust supplier qualification, auditing, quality agreements, and dual-sourcing strategies are central to Vertex's supply chain risk mitigation.
• All suppliers must adhere to strict global regulatory requirements, primarily Good Manufacturing Practices (GMP), with potential for Drug Master File (DMF) submissions for API manufacturers.
• Potential supply chain risks include disruptions, quality failures, regulatory non-compliance, and IP issues, all of which Vertex actively manages through established protocols.
• Raw material pricing and availability are influenced by market volatility, supplier capacity, and regulatory compliance costs.

Frequently Asked Questions

1. Does Vertex Pharmaceuticals manufacture all Kalydeco API internally? Vertex Pharmaceuticals likely utilizes a combination of internal manufacturing and external contract manufacturing organizations (CMOs) to produce the ivacaftor API, a common strategy to ensure supply chain resilience and capacity.

2. Are the specific CMOs involved in Kalydeco manufacturing publicly disclosed? Pharmaceutical companies typically do not publicly disclose the specific names of their contract manufacturing partners due to confidentiality and proprietary business agreements.

3. What are the primary quality control measures applied to Kalydeco's raw materials and API? Key quality control measures include adherence to Good Manufacturing Practices (GMP), rigorous testing of incoming raw materials and manufactured intermediates, process validation, and final API release testing against predefined specifications for purity, potency, and impurity profiles.

4. How does Vertex ensure the security and integrity of its Kalydeco supply chain against counterfeiting? Vertex implements measures such as serialization and track-and-trace systems, secure packaging, and rigorous supplier vetting to combat counterfeiting and ensure product integrity throughout the supply chain.

5. What is the typical lead time for sourcing critical raw materials for ivacaftor synthesis? Lead times for critical raw materials can vary significantly depending on the complexity of the chemical synthesis, global demand, and the supplier's production schedule, often ranging from several weeks to several months.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP) Resources. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practices-gmp-resources [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/good-manufacturing-practice [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/drug-master-files-dmfs [4] Vertex Pharmaceuticals Incorporated. (2023). Form 10-K Annual Report. U.S. Securities and Exchange Commission. [5] Pharmaceutical Technology. (n.d.). Excipients. Retrieved from https://www.pharmaceutical-technology.com/analysis/excipients-in-pharmaceuticals/